Matricelf Israeli Company

Matricelf has developed a technology that enables the production of autologous engineered tissue composed of matrix and cells derived from patients omental biopsies. In 2019, Matricelf licensed the technology that enabled scientists at Tel Aviv university to 3D print a human heart from human cells and matrix for the first time in history.